Direct magnetic resonance imaging-guided biopsy of the prostate

Lessons learned in establishing a regional referral center

Benjamin Addicott, Bryan Foster, Chenara Johnson, Alice Fung, Christopher Amling, Fergus Coakley

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

MRI-targeted biopsy of the prostate appears to have the potential to reduce the high rates of underdiagnosis and overdiagnosis associated with the current diagnostic standard of transrectal ultrasound guided systematic biopsy. Direct or "in bore" MRI-guided biopsy is one of the three methods for MRItargeted core needle sampling of suspicious, generally Pi-RADS 4 or 5, foci within the prostate, and our early experience suggests the approach demonstrates substantial utility and promise in the care of patients with prostate cancer. We performed direct MRI-guided biopsies in 50 patients within 19 months of establishing the first referral center for this service in our region. Our preliminary results indicate the service can be easily grown due to unmet demand, primarily in patients with a negative traditional systematic biopsy but with a concerning focus at MRI (30 of 50; 60%). Other applications include evaluation of patients who are on active surveillance (n=14; ten upgraded to higher Gleason score at MRI-guided biopsy), who are biopsy naïve (n=5; all positive at MRI-guided biopsy), or post focal therapy (n=1; positive for recurrent tumor at MRIguided biopsy). With careful patient selection and technique, we have achieved a favorable overall positive biopsy rate of 73% (37 of 50), with 84% (31 of 37) positive biopsies demonstrating Gleason score 7 or greater disease. Large multicenter comparative trials will be required to determine the relative accuracy and appropriate utilization of direct MRI guided biopsy in the care pathway of patients with known or suspected prostate cancer.

Original languageEnglish (US)
Pages (from-to)395-405
Number of pages11
JournalTranslational Andrology and Urology
Volume6
Issue number3
DOIs
StatePublished - Jun 1 2017

Fingerprint

Image-Guided Biopsy
Prostate
Referral and Consultation
Magnetic Resonance Imaging
Biopsy
Neoplasm Grading
Prostatic Neoplasms
Patient Care
Patient Selection
Multicenter Studies

Keywords

  • MRI
  • Prostate biopsy
  • Prostate cancer

ASJC Scopus subject areas

  • Reproductive Medicine
  • Urology

Cite this

Direct magnetic resonance imaging-guided biopsy of the prostate : Lessons learned in establishing a regional referral center. / Addicott, Benjamin; Foster, Bryan; Johnson, Chenara; Fung, Alice; Amling, Christopher; Coakley, Fergus.

In: Translational Andrology and Urology, Vol. 6, No. 3, 01.06.2017, p. 395-405.

Research output: Contribution to journalReview article

@article{dfc0219532ac44d29a74f0184c4fe094,
title = "Direct magnetic resonance imaging-guided biopsy of the prostate: Lessons learned in establishing a regional referral center",
abstract = "MRI-targeted biopsy of the prostate appears to have the potential to reduce the high rates of underdiagnosis and overdiagnosis associated with the current diagnostic standard of transrectal ultrasound guided systematic biopsy. Direct or {"}in bore{"} MRI-guided biopsy is one of the three methods for MRItargeted core needle sampling of suspicious, generally Pi-RADS 4 or 5, foci within the prostate, and our early experience suggests the approach demonstrates substantial utility and promise in the care of patients with prostate cancer. We performed direct MRI-guided biopsies in 50 patients within 19 months of establishing the first referral center for this service in our region. Our preliminary results indicate the service can be easily grown due to unmet demand, primarily in patients with a negative traditional systematic biopsy but with a concerning focus at MRI (30 of 50; 60{\%}). Other applications include evaluation of patients who are on active surveillance (n=14; ten upgraded to higher Gleason score at MRI-guided biopsy), who are biopsy na{\"i}ve (n=5; all positive at MRI-guided biopsy), or post focal therapy (n=1; positive for recurrent tumor at MRIguided biopsy). With careful patient selection and technique, we have achieved a favorable overall positive biopsy rate of 73{\%} (37 of 50), with 84{\%} (31 of 37) positive biopsies demonstrating Gleason score 7 or greater disease. Large multicenter comparative trials will be required to determine the relative accuracy and appropriate utilization of direct MRI guided biopsy in the care pathway of patients with known or suspected prostate cancer.",
keywords = "MRI, Prostate biopsy, Prostate cancer",
author = "Benjamin Addicott and Bryan Foster and Chenara Johnson and Alice Fung and Christopher Amling and Fergus Coakley",
year = "2017",
month = "6",
day = "1",
doi = "10.21037/tau.2017.01.14",
language = "English (US)",
volume = "6",
pages = "395--405",
journal = "Translational Andrology and Urology",
issn = "2223-4683",
publisher = "AME Publishing Company",
number = "3",

}

TY - JOUR

T1 - Direct magnetic resonance imaging-guided biopsy of the prostate

T2 - Lessons learned in establishing a regional referral center

AU - Addicott, Benjamin

AU - Foster, Bryan

AU - Johnson, Chenara

AU - Fung, Alice

AU - Amling, Christopher

AU - Coakley, Fergus

PY - 2017/6/1

Y1 - 2017/6/1

N2 - MRI-targeted biopsy of the prostate appears to have the potential to reduce the high rates of underdiagnosis and overdiagnosis associated with the current diagnostic standard of transrectal ultrasound guided systematic biopsy. Direct or "in bore" MRI-guided biopsy is one of the three methods for MRItargeted core needle sampling of suspicious, generally Pi-RADS 4 or 5, foci within the prostate, and our early experience suggests the approach demonstrates substantial utility and promise in the care of patients with prostate cancer. We performed direct MRI-guided biopsies in 50 patients within 19 months of establishing the first referral center for this service in our region. Our preliminary results indicate the service can be easily grown due to unmet demand, primarily in patients with a negative traditional systematic biopsy but with a concerning focus at MRI (30 of 50; 60%). Other applications include evaluation of patients who are on active surveillance (n=14; ten upgraded to higher Gleason score at MRI-guided biopsy), who are biopsy naïve (n=5; all positive at MRI-guided biopsy), or post focal therapy (n=1; positive for recurrent tumor at MRIguided biopsy). With careful patient selection and technique, we have achieved a favorable overall positive biopsy rate of 73% (37 of 50), with 84% (31 of 37) positive biopsies demonstrating Gleason score 7 or greater disease. Large multicenter comparative trials will be required to determine the relative accuracy and appropriate utilization of direct MRI guided biopsy in the care pathway of patients with known or suspected prostate cancer.

AB - MRI-targeted biopsy of the prostate appears to have the potential to reduce the high rates of underdiagnosis and overdiagnosis associated with the current diagnostic standard of transrectal ultrasound guided systematic biopsy. Direct or "in bore" MRI-guided biopsy is one of the three methods for MRItargeted core needle sampling of suspicious, generally Pi-RADS 4 or 5, foci within the prostate, and our early experience suggests the approach demonstrates substantial utility and promise in the care of patients with prostate cancer. We performed direct MRI-guided biopsies in 50 patients within 19 months of establishing the first referral center for this service in our region. Our preliminary results indicate the service can be easily grown due to unmet demand, primarily in patients with a negative traditional systematic biopsy but with a concerning focus at MRI (30 of 50; 60%). Other applications include evaluation of patients who are on active surveillance (n=14; ten upgraded to higher Gleason score at MRI-guided biopsy), who are biopsy naïve (n=5; all positive at MRI-guided biopsy), or post focal therapy (n=1; positive for recurrent tumor at MRIguided biopsy). With careful patient selection and technique, we have achieved a favorable overall positive biopsy rate of 73% (37 of 50), with 84% (31 of 37) positive biopsies demonstrating Gleason score 7 or greater disease. Large multicenter comparative trials will be required to determine the relative accuracy and appropriate utilization of direct MRI guided biopsy in the care pathway of patients with known or suspected prostate cancer.

KW - MRI

KW - Prostate biopsy

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85020960765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020960765&partnerID=8YFLogxK

U2 - 10.21037/tau.2017.01.14

DO - 10.21037/tau.2017.01.14

M3 - Review article

VL - 6

SP - 395

EP - 405

JO - Translational Andrology and Urology

JF - Translational Andrology and Urology

SN - 2223-4683

IS - 3

ER -